Annelot F. Schoffelen

Annelot F. Schoffelen

Auto-generated profile, based on publicly available information

Annelot F. Schoffelen

Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Eurosurveillance
Verified
Journal Article
Open access
RZRomy Zwittink
Romy Zwittink
CWCornelia Christina Henrica Wielders
Cornelia Christina Henrica Wielders
DNDaan W Notermans
Daan W Notermans
NVNelianne J. Verkaik
Nelianne J. Verkaik
ASAnnelot F Schoffelen
Annelot F Schoffelen
MGMRSA Surveillance Study Groups
MRSA Surveillance Study Groups
Since March 2022, there has been an emergence of multidrug-resistant organisms (MDRO) in the Netherlands in patients originating from Ukraine (58 patients, 75 isolates). For about half of these patients, recent hospitalisation in Ukraine was reported. Genomic surveillance revealed that the majority of the MDRO represent globally spread epidemic lineages and that 60% contain New Delhi metallo-β-lactamase (NDM) genes. Professionals should be aware of an increase in such MDRO associated with migration and medical evacuation of people from Ukraine.

25 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JPJannette Pirzadian
Jannette Pirzadian
MPMarjolein C. Persoon
Marjolein C. Persoon
JSJuliëtte A. Severin
Juliëtte A. Severin
CKCorné H. W. Klaassen
Corné H. W. Klaassen
SGSabine C. de Greeff
Sabine C. de Greeff
MVMargreet C. Vos
Margreet C. Vos
Verona Integron-encoded Metallo-beta-lactamase (VIM) is the most frequently-encountered carbapenemase in the healthcare-related pathogen Pseudomonas aeruginosa. In the Netherlands, a low-endemic country for antibiotic-resistant bacteria, no national surveillance data on the prevalence of carbapenemase-producing P. aeruginosa (CPPA) was available. Therefore, in 2016, a national surveillance pilot study was initiated to investigate the occurrence, molecular epidemiology, genetic characterization, and resistomes of CPPA among P. aeruginosa isolates submitted by medical microbiology laboratories (MMLs) throughout the country. From 1221 isolates included in the study, 124 (10%) produced carbapenemase (CIM-positive); of these, the majority (95, 77%) were positive for the blaVIM gene using PCR. Sequencing was performed on 112 CIM-positive and 56 CIM-negative isolates (n = 168), and genetic clustering revealed that 75/168 (45%) isolates were highly similar. This genetic cluster, designated Group 1, comprised isolates that belonged to high-risk sequence type ST111/serotype O12, had similar resistomes, and all but two carried the blaVIM-2 allele on an identical class 1 integron. Additionally, Group 1 isolates originated from around the country (i.e. seven provinces) and from multiple MMLs. In conclusion, the Netherlands had experienced a nationwide, inter-institutional, clonal outbreak of VIM-2-producing P. aeruginosa for at least three years, which this pilot study was crucial in identifying. A structured, national surveillance program is strongly advised to monitor the spread of Group 1 CPPA, to identify emerging clones/carbapenemase genes, and to detect transmission in and especially between hospitals in order to control current and future outbreaks.

8 December 2022 in Eurosurveillance
Verified
Journal Article
Open access
KVKaruna E.W. Vendrik
Karuna E.W. Vendrik
EKEd J. Kuijper
Ed J. Kuijper
MDMarieke Dimmendaal
Marieke Dimmendaal
WSWelmoed Silvis
Welmoed Silvis
EDEls Denie-Verhaegh
Els Denie-Verhaegh
MCMRSA consortium
MRSA consortium
In this retrospective observational study, we analysed a community outbreak of impetigo with meticillin-resistant Staphylococcus aureus (MRSA), with additional resistance to fusidic acid (first-line treatment). The outbreak occurred between June 2018 and January 2020 in the eastern part of the Netherlands with an epidemiological link to three cases from the north-western part. Forty nine impetigo cases and eight carrier cases were identified, including 47 children. All but one impetigo case had community-onset of symptoms. Pharmacy prescription data for topical mupirocin and fusidic acid and GP questionnaires suggested an underestimated outbreak size. The 57 outbreak isolates were identified by the Dutch MRSA surveillance as MLVA-type MT4627 and sequence type 121, previously reported only once in 2014. Next-generation sequencing revealed they contained a fusidic acid resistance gene, exfoliative toxin genes and an epidermal cell differentiation inhibitor gene. Whole-genome multilocus sequence typing revealed genetic clustering of all 19 sequenced isolates from the outbreak region and isolates from the three north-western cases. The allelic distances between these Dutch isolates and international isolates were high. This outbreak shows the appearance of community-onset MRSA strains with additional drug resistance and virulence factors in a country with a low prevalence of antimicrobial resistance.

29 September 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
DNDaan W Notermans
Daan W Notermans
ASAnnelot F Schoffelen
Annelot F Schoffelen
FLFabian Landman
Fabian Landman
CWCornelia Christina Henrica Wielders
Cornelia Christina Henrica Wielders
SWSandra Witteveen
Sandra Witteveen
AHAntoni P.A. P.A. Hendrickx
Antoni P.A. P.A. Hendrickx
Carbapenemase-producing Enterobacterales (CPE) represent an increasing global problem. Since 2016, the carbapenemase oxacillinase (OXA)-244, a single amino-acid variant of OXA-48 and present in Escherichia coli ST38, has been recognized as an emerging carbapenemase variant in several European countries. This prompted the ECDC to publish a rapid risk assessment in February 2021 with a follow-up in July.1 The increase of OXA-244 was also observed in the Netherlands after analysis of the data from the Dutch national CPE surveillance. For the Dutch CPE surveillance, medical microbiology laboratories are requested to send isolates suspected of carbapenemase production, with a meropenem MIC of ≥0.25 mg/L and/or an imipenem MIC of ≥1 mg/L, or evidence of carbapenemase production, to the National Institute for Public Health and the Environment. Illumina next-generation sequencing (NGS) was performed on all isolates testing positive for carbapenemase production, from persons with a personal identifier code present to be able to detect multiple isolates from the same person.2 Between January 2016 and June 2021, from 1203 unique CPE isolates (unique combination of species and carbapenemase gene per person), NGS results were available. Of these, 394 (33%; 394/1203) isolates were E. coli and NGS data were used for Clermont phylotyping,3 classical MLST, whole-genome (wg)MLST analysis using an in-house E. coli wgMLST scheme, and core SNP analysis [Figure 1 and Figure S1(a and b), available as Supplementary data at JAC Online] .4 Among the 394 sequenced carbapenemase-producing E. coli isolates, 85 were MLST ST38, of which 30 contained blaOXA-244. Seventeen of these 30 OXA-244-producing ST38 E. coli isolates formed a genetic cluster based on wgMLST and was termed EcoCluster-023. A genetic wgMLST cluster is defined as ≥2 isolates that differ by ≤25 wgMLST alleles.4 The 17 EcoCluster-023 isolates differed by 1 to 21 wgMLST alleles from each other [Figure 1(b)]. In addition, core SNP analysis revealed 1 to 62 SNP differences among the 17 EcoCluster-023 isolates. [Figure S1(a and b) ]. The wgMLST allelic variation and SNP differences may be explained since isolates were from cultures taken between August 2016 and May 2021, with 13 (76%) isolates from 2020 and 2021. The 17 isolates were derived from 17 different patients, and were submitted by 13 different laboratories from eight different provinces. The median age of the patients was 54 years (range 8 to 92) and 10 (59%) patients were women. Nine (53%) isolates were cultured from urine, and the other eight from rectal swabs. This percentage of isolates derived from urine cultures was considerably higher than the 80 (21.2%) among the other 377 carbapenemase-producing E. coli isolates from this study excluding this cluster. All EcoCluster-023 isolates produced carbapenemase, as tested with the carbapenem inactivation method.5 The MIC of meropenem was below 1.5 mg/L for all isolates, as determined by Etest, therefore all isolates were susceptible according to EUCAST [Figure 1(c)]. Information on risk factors was available for 16 patients. There was no evidence for direct patient-to-patient transmission in this group. Eight (50%) persons had a known connection with Middle Eastern countries, Turkey in five patients and Syria in three. This was either as recent hospitalization in the previous 2 months (n = 2) or up to a year ago (n = 3), or as country of birth (n = 6, including three with previous hospitalization there). Recent hospitalization abroad up to 2 months previous, is considered a risk factor in Dutch national guidelines. The prevalence of OXA-244 in Middle Eastern countries is unknown.

14 December 2023 in Eurosurveillance
Verified
Journal Article
Open access
WKWieke Altorf-Van der Kuil
Wieke Altorf-Van der Kuil
CWCornelia Christina Henrica Wielders
Cornelia Christina Henrica Wielders
RZRomy Zwittink
Romy Zwittink
SGSabine C de Greeff
Sabine C de Greeff
DDDave A Dongelmans
Dave A Dongelmans
OGon behalf of the study collaborators ISIS-AR study group
on behalf of the study collaborators ISIS-AR study group
Background: The COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling.Aim: To gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020).Methods: We investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions.Results: Although no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistantStaphylococcus aureusduring waves and lower prevalence of multidrug-resistantPseudomonas aeruginosaduring interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures withEnterococcus faecium(pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19.Conclusion: We observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.

7 April 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
MAMax P. Allewijn
Max P. Allewijn
SWSandra Witteveen
Sandra Witteveen
KVKaruna E. W. Vendrik
Karuna E. W. Vendrik
AHAngela de Haan
Angela de Haan
FLFabian Landman
Fabian Landman
AHAntoni P.A. P.A. Hendrickx
Antoni P.A. P.A. Hendrickx
We investigated the genomic epidemiology of carbapenem-resistant Acinetobacter baumannii (CRAb) during two surveillance periods: 2015–2017 (pilot 1) and 2022–2024 (pilot 2) in an international context to identify potential circulating high-risk lineages in the Netherlands. A total of 204 CRAb isolates were all analyzed by the carbapenem inactivation method, meropenem Etest, and whole-genome sequencing (combining Illumina and Nanopore). Comparative resistome, multilocus sequence typing (MLST), and whole-genome MLST (wgMLST) analyses were performed between pilots and compared to 577 international CRAb genomes. The Dutch CRAb population remained genetically diverse and stable between pilots and was dominated by international clone (IC)2 (61.8%), followed by IC9 (11.3%), IC1 (6.4%), and IC6 (5.9%). Also, epidemiological and clinical characteristics remained stable across both pilots. In contrast, CRAb in patients from Ukraine was genetically diverse and an epidemiologically distinct group. wgMLST indicated an increase in genetic clustering in 2022–2024, with unique CRAb clusters associated with Ukrainian patients. Of 26 identified clusters, 69% were linked to international sources. Differences in resistomes were observed between CRAb in patients from the Netherlands and Ukraine, and between pilots. Overall, 75% of isolates harbored bla OXA-23 -like genes, and bla NDM genes increased from 16% to 21%. None of the CRAb isolates from Ukrainian patients carried bla NDM genes; instead, they harbored bla OXA-23 -like and bla OXA-24 -like genes. Hybrid assemblies showed that carbapenemase genes were predominantly chromosomal. In conclusion, CRAb in the Netherlands showed genetic stability over time, yet the presence of New Delhi metallo-β-lactamase-carbapenemases and import of strains from high-risk regions underline the necessity for ongoing national surveillance. IMPORTANCE: In 2015–2017 and 2022–2024, pilot surveillance of carbapenem-resistant Acinetobacter baumannii (CRAb) was performed in the Netherlands. Three distinct groups were compared based on epidemiological and genomic data: CRAb from 2015 to 2017 and for the 2022–2024 period, CRAb in patients from the Netherlands, and CRAb in patients from Ukraine in the Netherlands. The genomic epidemiology of CRAb has been mostly stable between 2015–2017 and 2022–2024 but seems to be strongly affected by the introduction of CRAb from foreign countries. A proportion of the 2022–2024 isolates were from Ukrainian patients. The resistance genes of CRAb from Ukrainian patients were different from those of the Netherlands. CRAb in the Netherlands are acquiring New Delhi metallo-β-lactamase-carbapenemase genes, aided by the introduction of CRAb from foreign countries. Healthcare professionals should remain aware of the risk of hospitalization in a high-risk country and the potential secondary transmission of CRAb to patients in countries with a low prevalence of this organism.